Latin America peptide regulation overview

Latin America has no single regional regulatory regime. Each country has its own drug regulatory authority, although PAHO/WHO's PANDRH network promotes harmonisation. Most jurisdictions require marketing authorisation for peptide medicines. Compounding (manipulação / magistral preparation) is permitted within defined legal boundaries but the use of unauthorised peptide bulk substances is generally not allowed.

• PAHO / PANDRH (Pan American Network for Drug Regulatory Harmonisation): promotes convergence of regulatory requirements. A 2025 MOU with AEMPS (Spain) supports interagency exchange. The Pacific Alliance Agreement (Mexico, Colombia, Chile, Peru) facilitates regulatory cooperation but does not create a single regime.

• National authorities: see dedicated pages for Brazil (ANVISA), Mexico (COFEPRIS), and Argentina/Colombia/Chile (ANMAT, INVIMA, ISP).

1. Marketing authorisation: the jurisdictions covered by the linked country pages generally require registration before commercial sale of a peptide medicine, subject to national exceptions. Approved products include GLP-1 receptor agonists, insulins, GnRH analogues, and somatostatin analogues.

2. Compounding: several reviewed countries allow pharmacy compounding for individual patients, but require: (a) a valid prescription; (b) use of approved or pharmacopoeial raw materials; (c) the product not be a copy of an approved commercial drug.

3. Research-use-only: in the jurisdictions reviewed, RUO wording was not identified as a safe harbour when surrounding facts show human-use marketing.

4. Import: commercial import generally requires national authorization. Personal-use, clinical-trial and named-patient pathways vary by country and must be checked in the current national rules.

5. Enforcement: uneven across the region. Brazil and Mexico have the most active enforcement programmes; the ANMAT (Argentina) and INVIMA (Colombia) have issued alerts against falsified and unapproved peptide products.

WADA Prohibited List S2 applies through national anti-doping organisations in each country. Enforcement capacity varies significantly.

This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.

1. PAHO — PANDRH. https://www.paho.org/en/pan-american-network-drug-regulatory-harmonization-pandrh

2. ANVISA. https://www.gov.br/anvisa

3. COFEPRIS. https://www.gob.mx/cofepris

4. ANMAT. https://www.argentina.gob.ar/anmat

5. INVIMA. https://www.invima.gov.co

6. ISP Chile. https://www.ispch.cl